[ad_1]
DUBLIN, July 26, 2019 / PRNewswire / – The report "The Global Market for Liquid Biopsy" has been added to ResearchAndMarkets.com & # 39; s offer.
Liquid biopsies are a set of minimally invasive diagnostic methods that badyze tumor-derived materials that can circulate in biological fluids to provide information for the diagnosis, treatment, and monitoring of cancer.
This report, The Global Liquid Biopsy Market, contains up-to-date information and data points useful for planning activities:
- Research vs clinical fluid biopsy
- The liquid biopsy market by region
- The liquid biopsy market market by type of badyte
- The CTC-based liquid biopsy market
- The cDNA-based liquid biopsy market
- The EV-based liquid biopsy market and exosomes
- The multi-badyte liquid biopsy market
- The market for other liquid biopsies
- Market liquid biopsies by type of cancer (bad cancer, lung cancer, colorectal, ovarian, prostate, pan-cancer, other cancer)
- Selected liquid biopsy tests based on developing cDNA
- CLC-based liquid biopsy tests available on the market, 2019
- Selected Liquid Biopsy Assays Evaluating Multiple Analytes, 2019
Tissue biopsies and imaging techniques remain the current standards of care for the diagnosis of solid tumors, but they carry risks, as well as limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to treatment. current standards of care.
Liquid phase biopsy badays have many potential applications in aspects of clinical oncology, including:
- Early detection and diagnosis / screening
- Alternative test method when tissue biopsy is difficult / impossible or when the primary site of metastatic disease is unknown
- Personalization and treatment monitoring – by characterizing a patient's disease in a molecular way, clinicians can choose the optimal treatment and monitor its effectiveness over time, as well as react quickly to adjust treatment in case resistance of the treatment.
- Disease Surveillance – to observe disease progression, tumor evolution, residual disease and early detection of recurrence
- Prognosis of the disease
Key topics covered:
Chapter One: Summary
- introduction
- Liquid biopsy technologies
- Structure of the industry
- Revenues and forecasts of the liquid biopsy market
Chapter Two: Liquid Biopsy Technologies
- introduction
- Main current technologies of liquid biopsy
Chapter Three: Circulating Tumor Liquid Fluid Biopsy (ctDNA)
- introduction
- Advantages and limitations of cDNA in liquid biopsy
- CDNA-based liquid phase biopsy tests
- Biocartis
- Biocept
- Biodesix
- CellMax Life
- Circulogène
- Diacarta
- epigenomics
- Basic medicine
- Guardian's health
- Inivata
- LungLife AI
- Myriad Genetics
- NeoGenomics
- OncoDNA
- Personal genomic diagnosis
- QIAGEN
- Biosciences Resolution
- Roche Diagnostics
- Sysmex-Inostics
- CtADn-based liquid biopsy tests in development
- Exact Sciences
- Freenome
- GRAIL
- Personal diagnosis of the genome
- Tempus
Chapter Four: Liquid Circulating Tumor Cell Biopsy (CTC)
- introduction
- Challenges in the development of CTC-based liquid biopsy tests
- CTC-based liquid biopsy tests
- Adaptive biotechnologies
- Biocept
- CellMax Life
- Epic Sciences
- GILUPI
- LungLife AI
- Biosystems Menarini-Silicon
- QIAGEN
- CTC-based liquid biopsy tests under development
- ANGLE
- Epic Sciences
- Liquid Biotech United States
Chapter Five: Extracellular Vesicles and Other Liquid Biopsies
- introduction
- Extracellular vesicle / other badyte liquid biopsy tests
- Biodexis
- Diagnosis of exosome
- Hologic
- MDxHealth
- Vermillion
- Extracellular vesicle / other badytic-based liquid biopsy tests in development
- Circulogène
- OncoCyte
- QIAGEN
- Biosciences Resolution
- VolitionRx
Chapter Six: Multi-badyte Liquid Biopsy Tests
- introduction
- Liquid Biopsy Tests Based on Multiple Analytes
- Biocept
- Biodesix
- Basic medicine
- LungLife AI
- NeoGenomics
- OncoDNA
- Several developing liquid biopsy-based badyte tests
- Exact Sciences
- Freenome
- GRAIL
- LungLife AI
Chapter Seven: Liquid Biopsy Tests for Research Purposes Only
- introduction
- Liquid biopsy tests for research purposes only
- Agena Bioscience
- ANGLE
- DiaCarta
- Diagnosis of exosome
- Guardian's health
- Natera
- QIAGEN
Chapter Eight: Analysis of the Liquid Biopsy Sector
- introduction
- Levels of competition
- Competitive factors
- Significant market trends
- Personalized medicine
- Increasing global life expectancy
- New liquid biopsy products
- Increase in the accessibility of genetic tests
- Regulatory hurdles
- Third Party Coverage
- Demonstrated clinical utility
- Incidence rate of some cancers
- Competitors are no longer in the liquid biopsy market
Chapter Nine: Liquid Biopsy Market
- Market overview
- Market Forecast
Chapter ten: Market by badyte
- Tumor DNA in circulation
- Market overview
- Revenue Forecasts
- Circulating tumor cells
- Market overview
- Revenue Forecasts
- Extracellular vesicles and other badytes
- Market overview
- Revenue Forecasts
- Several badytes
- Market overview
- Revenue Forecasts
- Table 10-4: Global Liquid Biopsy Market for Multiple Analytes ($ Millions), 2018-2023
Chapter Eleven: Market by Application
- Therapeutic guidance and monitoring
- Market overview
- Revenue Forecasts
- Diagnosis / Screening
- Market overview
- Revenue Forecasts
- Prognosis of the disease
- Market overview
- Revenue Forecasts
Chapter Twelve: Market by Type of Cancer
- Breast cancer
- Market overview
- Revenue Forecasts
- Colorectal cancer
- Market overview
- Revenue Forecasts
- Lung cancer
- Ovarian cancer
- Prostate cancer
- Other cancers
- Pan-Cancer Tests
Chapter thirteen: Profiles of liquid biopsy companies
- Top ten companies in the liquid biopsy market
- Adaptive biotechnologies
- Agena Bioscience, Inc.
- ANGLE, plc
- Biocartis Group NV
- Biocept, Inc.
- Biodesix
- CellMax Life
- Circulogène
- DiaCarta, Inc.
- Epic Sciences
- Epigenomics AG
- Exact Sciences
- Exosome Diagnostics, Inc.
- Medicine Foundation, Inc.
- Freenome, Inc.
- Genomic Health, Inc.
- GILUPI GmbH
- GRAIL
- Guardant Health, Inc.
- Hologic
- Inivata
- Liquid Biotech United States
- LungLife AI (formerly Cynvenio Biosystems)
- MDxHealth
- Biosystems Menarini-Silicon, Spa
- Myriad Genetics, Inc.
- Natera, Inc.
- NeoGenomics Laboratories, Inc.
- OncoCyte Corporation
- OncoDNA S.A.
- Personal diagnosis of the genome
- QIAGEN N.V.
- Cell-free DNA technologies
- CTC Technologies
- Exosome and miRNA technologies
- Biosciences Resolution
- Roche Diagnostics
- Sysmex-Inostics, Inc.
- Tempus
- Vermillion, Inc.
- VolitionRx
For more information on this report, visit https://www.researchandmarkets.com/r/1xjxk6.
Research and Markets also offers customized research services that provide targeted, comprehensive and personalized research.
Media contact:
Laura Wood, Main director
[email protected]
For E.S.T office hours, call + 1-917-300-0470
For toll-free calls to the United States and Canada + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900
American fax: 646-607-1907
Fax (outside the United States): + 353-1-481-1716
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com
Source link
